Niagen Bioscience (NAGE) Other financing activities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Other financing activities of $111000.0 for Q1 2026, down 96.44% year-over-year from $3.1 million in Q1 2025, and down 51.32% quarter-over-quarter from $228000.0 in Q4 2025.
Niagen Bioscience (NAGE) Other financing activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Other financing activities for 12 consecutive years, with $111000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 96.44% year-over-year to $111000.0; the TTM figure through Mar 2026 stood at $4.2 million (down 50.35% YoY), while the FY2025 annual figure was $7.2 million, up 33.39% from the prior year.
- Other financing activities slipped to $111000.0 in Q1 2026 per NAGE's latest filing, from $228000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3.8 million in Q4 2024 and bottomed at $111000.0 in Q1 2026.
- Historically, Other financing activities has averaged $1.6 million across 3 years, with a median of $820500.0 in 2024.
- Annual changes were most pronounced in 2025 — Other financing activities jumped 527.42% — and 2026, when it sank 96.44%.
- Niagen Bioscience's Other financing activities stood at $3.8 million in 2024, then slumped by 93.99% to $228000.0 in 2025, then sank by 51.32% to $111000.0 in 2026.
- Business Quant data shows NAGE's Other financing activities at $111000.0 in Q1 2026, $228000.0 in Q4 2025, and $152000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206,000.00 |
| Jun 30, 2026 | 206,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 3.75 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 598,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Dec 31, 2021 | 130,000.00 |
| Dec 31, 2021 | 130,000.00 |